[C]PK11195 Binding in Alzheimer Disease and Progressive Supranuclear Palsy

Overview

Journal Neurology

Specialty Neurology

Date 2018 Apr 29

PMID 29703774

Citations 58

Authors

Luca Passamonti

Patricia Vazquez Rodriguez

Young T Hong

Kieren S J Allinson

W Richard Bevan-Jones

David Williamson

P Simon Jones

Robert Arnold

Robin J Borchert

Ajenthan Surendranathan

Elijah Mak

Li Su

Tim D Fryer

Franklin I Aigbirhio

John T OBrien

James B Rowe

Affiliations

Soon will be listed here.

Abstract

Objective: We tested whether in vivo neuroinflammation relates to the distinctive distributions of pathology in Alzheimer disease (AD) and progressive supranuclear palsy (PSP).

Methods: Sixteen patients with symptomatic AD (including amnestic mild cognitive impairment with amyloid-positive PET scan), 16 patients with PSP-Richardson syndrome, and 13 age-, sex-, and education-matched healthy controls were included in this case-control study. Participants underwent [C]PK11195 PET scanning, which was used as an in vivo index of neuroinflammation.

Results: [C]PK11195 binding in the medial temporal lobe and occipital, temporal, and parietal cortices was increased in patients with AD, relative both to patients with PSP and to controls. Compared to controls, patients with PSP showed elevated [C]PK11195 binding in the thalamus, putamen, and pallidum. [C]PK11195 binding in the cuneus/precuneus correlated with episodic memory impairment in AD, while [C]PK11195 binding in the pallidum, midbrain, and pons correlated with disease severity in PSP.

Conclusions: Together, our results suggest that neuroinflammation has an important pathogenic role in the 2 very different human neurodegenerative disorders of AD and PSP. The increase and distribution of microglial activation suggest that immunotherapeutic strategies may be useful in slowing the progression of both diseases.

Citing Articles

Brainstem and cerebellar radiological findings in progressive supranuclear palsy.

Spiegel C, Marotta C, Bertram K, Vivash L, Harding I Brain Commun. 2025; 7(1):fcaf051.

PMID: 39958262 PMC: 11829206. DOI: 10.1093/braincomms/fcaf051.

Possible Impact of Peripheral Inflammatory Factors and Interleukin-1β (IL-1β) on Cognitive Functioning in Progressive Supranuclear Palsy-Richardson Syndrome (PSP-RS) and Progressive Supranuclear Palsy-Predominant Parkinsonism (PSP-P).

Chunowski P, Otto-Slusarczyk D, Duszynska-Was K, Drzewinska A, Zaleski A, Madetko-Alster N Int J Mol Sci. 2024; 25(23).

PMID: 39684921 PMC: 11642545. DOI: 10.3390/ijms252313211.

Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer's disease.

Zatcepin A, Gnorich J, Rauchmann B, Bartos L, Wagner S, Franzmeier N Mol Neurodegener. 2024; 19(1):64.

PMID: 39238030 PMC: 11375924. DOI: 10.1186/s13024-024-00752-6.

Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration.

Malpetti M, Swann P, Tsvetanov K, Chouliaras L, Strauss A, Chikaura T Brain. 2024; 148(2):493-505.

PMID: 39155063 PMC: 7617268. DOI: 10.1093/brain/awae269.

Translocator protein (18 kDa) positron emission tomography imaging as a biomarker of neuroinflammation in epilepsy.

Qin L, Xiao L, Zhu H, Du Y, Tang Y, Feng L Neurol Sci. 2024; 45(11):5201-5211.

PMID: 38879831 DOI: 10.1007/s10072-024-07648-9.

References

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Yokokura M, Terada T, Bunai T, Nakaizumi K, Takebayashi K, Iwata Y . Depiction of microglial activation in aging and dementia: Positron emission tomography with [C]DPA713 versus [C]( R)PK11195. J Cereb Blood Flow Metab. 2016; 37(3):877-889. PMC: 5363467. DOI: 10.1177/0271678X16646788. View

Bevan-Jones W, Surendranathan A, Passamonti L, Vazquez Rodriguez P, Arnold R, Mak E . Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open. 2017; 7(1):e013187. PMC: 5223666. DOI: 10.1136/bmjopen-2016-013187. View

Jabbari E, Zetterberg H, Morris H . Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry. 2017; 88(10):883-888. DOI: 10.1136/jnnp-2017-315857. View

Cagnin A, Brooks D, Kennedy A, Gunn R, Myers R, Turkheimer F . In-vivo measurement of activated microglia in dementia. Lancet. 2001; 358(9280):461-7. DOI: 10.1016/S0140-6736(01)05625-2. View

Scholl M, Lockhart S, Schonhaut D, ONeil J, Janabi M, Ossenkoppele R . PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016; 89(5):971-982. PMC: 4779187. DOI: 10.1016/j.neuron.2016.01.028. View

Agostinho P, Cunha R, Oliveira C . Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2010; 16(25):2766-78. DOI: 10.2174/138161210793176572. View

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112(4):389-404. PMC: 3906709. DOI: 10.1007/s00401-006-0127-z. View

Lyketsos C, Breitner J, Green R, Martin B, Meinert C, Piantadosi S . Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007; 68(21):1800-8. DOI: 10.1212/01.wnl.0000260269.93245.d2. View

10.

Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn N, Bhatia K, Brooks D . In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2005; 21(1):89-93. DOI: 10.1002/mds.20668. View

11.

Edison P, Archer H, Gerhard A, Hinz R, Pavese N, Turkheimer F . Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008; 32(3):412-9. DOI: 10.1016/j.nbd.2008.08.001. View

12.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

13.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley R . Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016; 139(Pt 4):1252-64. DOI: 10.1093/brain/aww017. View

14.

Golbe L, Ohman-Strickland P . A clinical rating scale for progressive supranuclear palsy. Brain. 2007; 130(Pt 6):1552-65. DOI: 10.1093/brain/awm032. View

15.

Schuitemaker A, Kropholler M, Boellaard R, van der Flier W, Kloet R, van der Doef T . Microglial activation in Alzheimer's disease: an (R)-[¹¹C]PK11195 positron emission tomography study. Neurobiol Aging. 2012; 34(1):128-36. DOI: 10.1016/j.neurobiolaging.2012.04.021. View

16.

Rojas J, Bang J, Lobach I, Tsai R, Rabinovici G, Miller B . CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2017; 90(4):e273-e281. PMC: 5798651. DOI: 10.1212/WNL.0000000000004859. View

17.

Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S . Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol. 2007; 193(1-2):183-7. DOI: 10.1016/j.jneuroim.2007.10.020. View

18.

Fan Z, Okello A, Brooks D, Edison P . Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. Brain. 2015; 138(Pt 12):3685-98. DOI: 10.1093/brain/awv288. View

19.

Hauw J, Daniel S, Dickson D, Horoupian D, Jellinger K, Lantos P . Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994; 44(11):2015-9. DOI: 10.1212/wnl.44.11.2015. View

20.

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View